ReviewNature reviews. Clinical oncology2013
Circulating tumour cells and cell-free DNA as tools for managing breast cancer.
Review in Nature reviews. Clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.Cancer medicine · 2019Pooled it
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.Nature communications · 2016Trial
- A Novel Sensitive Technique to DetectCancer innovation · 2026Article
- Analyzed PD-L1-positive subpopulations by dual-labeling TSA-IF-FISH predicts immunotherapy efficacy in advanced lung cancer.iScience · 2026Article
- Pangolin-type fluorescence imaging of circulating tumor cell based on functionalized 2D nanomaterial.Mikrochimica acta · 2025Article
- Review
- Advancements in Biotechnology and Stem Cell Therapies for Breast Cancer Patients.Current stem cell research & therapy · 2024Review
- Establishing Single-Cell Clones from In Vitro-Cultured Circulating Tumor Cells.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients.Scientific reports · 2023Article
- Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment.Medical oncology (Northwood, London, England) · 2023Review
- Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer.Scientific reports · 2023Article
- Plasma and Synovial Fluid Cell-Free DNA Concentrations Following Induction of Osteoarthritis in Horses.Animals : an open access journal from MDPI · 2023Article
- A novel platform using homobifunctional hydrazide for enrichment and isolation of urinary circulating RNAs.Bioengineering & translational medicine · 2023Article
- Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.Nature biomedical engineering · 2022Review
- Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.Cancer biology & therapy · 2021Article
- How to use liquid biopsies to treat patients with cancer.ESMO open · 2021Review
- Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA.Current treatment options in oncology · 2021Review
- T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer.Oncology letters · 2021Review
- Review
- Monte Carlo Modeling of Shortwave-Infrared Fluorescence Photon Migration in Voxelized Media for the Detection of Breast Cancer.Diagnostics (Basel, Switzerland) · 2020Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating blood biomarkers promise to become non-invasive real-time surrogates for tumour tissue-based biomarkers. Circulating biomarkers have been investigated as tools for breast cancer diagnosis, the dissection of breast cancer biology and its genetic and clinical heterogeneity, prognostication, prediction and monitoring of therapeutic response and resistance. Circulating tumour cells and cell-free plasma DNA have been analysed in retrospective studies, and the assessment of these biomarkers is being incorporated into clinical trials. As the scope of breast cancer intratumour genetic heterogeneity unravels, the development of robust and standardized methods for the assessment of circulating biomarkers will be essential for the realization of the potentials of personalized medicine. In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer.
Indexed as
Identifiers
23712187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.